AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia for patients experiencing acute pain episodes. AeroLEF™... AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain.
- Mechanism
- Curator reviewed
AeroLEF is developed to offer a simple and non-invasive route of administration, rapid onset of action, sustained effect and self-titratable dosing for the treatment of acute and breakthrough pain, conditions that are common in cancer patients and underserved by existing fixed-dose delivery technologies. Using AeroLEF, patients can identify and select a personalized dose for each pain episode, achieving both rapid onset and extended duration of analgesia.
- Primary indication
- Investigated for use/treatment in pain (acute or chronic).Curator reviewed
What you can answer from here — as of October 01, 2026
Which companies are running trials of AeroLEF, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account